Mirum Pharmaceuticals, Inc. is a high-risk biopharmaceutical company based in the United States that specializes in developing novel therapies for rare and orphan diseases. Their flagship product Livmarli is approved for treating cholestatic pruritus in patients with Alagille syndrome, with ongoing development of Maralixibat and volixibat for other liver diseases. With an ESG score of 32.2, Mirum Pharmaceuticals is committed to environmental, sustainability, and governance practices.